In asthma, the greatest reductions in eosinophils were seen with higher dosages, for example, a 64% reduction in eosinophils was seen with a 12.5mg SC dose and a 90% reduction was seen with a 250mg SC dose after 48 hours. Continue reading Can Nucala cause weight gain? Weight gain has...
Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.J Allergy Clin Immunol. 2019;143(5):1742-1751.e7. Felarca AB, Lowell FC. The total eosinophil count in a nonatopic popula...
*IQVIA National Prescription Audit from January 2023 to December 2023 for all indications combined. NUCALA is indicated for the add-on treatment of patients 6+ with severe eosinophilic asthma (SEA). Not for acute bronchospasm or status asthmaticus....
NUCALA is an add-on, prescription maintenance treatment for patients 6 and older with severe eosinophilic asthma. NUCALA is not used to treat sudden breathing problems. Learn about taking NUCALA at home Info about NUCALA sent straight to my inbox? Sign me up. By completing this form, you cert...
dose ICS plus additional controller(s) (Trials 1 and 2), and 135 patients required daily oral corticosteroids (OCS) in addition to regular use of high-dose ICS plus additional controller(s) to maintain asthma control (Trial 3). All patients had markers of eosinophilic airway inflammation [see...
patients with severe asthma receiving Nucala experienced greater reductions in their daily maintenance oral corticosteroid dose, while maintaining asthma control compared with patients receiving placebo. Treatment with mepolizumab did not result in a significant improvement in lung function, as measured by th...
Acute Asthma Symptoms or Deteriorating Disease NUCALA should not be used to treat acute asthma symptoms, acute exacerbations, or acute bronchospasm. Opportunistic Infections: Herpes Zoster Herpes zoster infections have occurred in patients receiving NUCALA. Consider vaccination if medically appropriate. ...
Learn about the anti-IL-5 mechanism of action of NUCALA (mepolizumab) and discover how it works to target eosinophils in patients with severe eosinophilic asthma.
Poor symptom control (frequent symptoms or reliever use, activity limited by asthma, night waking due to asthma);and Member has inadequate asthma control despite current treatment withbothof the following medications at optimized doses: High-dose inhaled corticosteroid;and ...
add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus. add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwN...